BriaCell highlights Bria-OTS+ cancer immunotherapy data in SITC 2026 poster presentation
BCTX•BriaCell Therapeutics said four preclinical immunotherapy posters were accepted for the SITC annual meeting in Phoenix on Nov. 4-8, 2026, with presentations scheduled for Nov. 6-7.
1. Posters accepted
BriaCell Therapeutics announced that four preclinical immunotherapy posters were accepted for the SITC annual meeting in Phoenix. The work includes early evidence on its vaccine platform and separate posters on tumor-targeted checkpoint approaches, including a soluble CD80 program.
